• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by bioAffinity Technologies Inc.

    10/10/23 6:03:06 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $BIAF alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    bioAffinity Technologies, Inc.

    (Name of Issuer)

     

    Common Stock, $0.007 par value per share

    (Title of Class of Securities)

     

    09076W109

    (CUSIP Number)

     

    Roby P. Joyce, M.D.

    c/o bioAffinity Technologies, Inc.

    22211 W Interstate 10, Suite 1206

    San Antonio, Texas 78257

    (210) 698-5334

    (Name, address and telephone number of person authorized to receive notices and communications)

     

    With a copy to:

     

    Leslie Marlow, Esq.

    Blank Rome LLP

    1271 Avenue of the Americas

    New York, New York 10020

    (212) 885-5000

     

    September 18, 2023

    (Date of event which requires filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 09076W109 SCHEDULE 13G Page 2 of 7 Pages

     

    1 NAME OF REPORTING PERSON  
         
      Roby P. Joyce  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
      5 SOLE VOTING POWER  
    NUMBER OF      
    SHARES   0  
    BENEFICIALLY 6 SHARED VOTING POWER  
    OWNED BY      
    EACH   603,129  
    REPORTING 7 SOLE DISPOSITIVE POWER  
    PERSON WITH      
        0  
      8 SHARED DISPOSITIVE POWER  
           
        603,129  
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      603,129 (1)  
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
         
         
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      6.44% (2)  
    12 TYPE OF REPORTING PERSON  
         
      IN  

     

      (1) Includes: 583,130 shares of common stock owned by The Joyce Living Trust (the “Trust”) and 19,999 shares of common stock issuable upon the exercise of warrants owned by the Trust.
      (2) This percentage is calculated based on 9,350,297 shares of the Common Stock issued and outstanding on September 20, 2023, as reported by the Issuer in the Issuer’s Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on September 20, 2023.

     

     

     

     

    CUSIP No. 09076W109 SCHEDULE 13G Page 3 of 7 Pages

     

    1 NAME OF REPORTING PERSON  
         
      The Joyce Living Trust  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Texas  
      5 SOLE VOTING POWER  
    NUMBER OF      
    SHARES   0  
    BENEFICIALLY 6 SHARED VOTING POWER  
    OWNED BY      
    EACH   603,129  
    REPORTING 7 SOLE DISPOSITIVE POWER  
    PERSON WITH      
        0  
      8 SHARED DISPOSITIVE POWER  
           
        603,129  
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      603,129 (1)  
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
         
         
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      6.44% (2)  
    12 TYPE OF REPORTING PERSON  
         
      OO  

     

      (1) Includes: 583,130 shares of common stock owned by the Trust and 19,999 shares of common stock issuable upon the exercise of warrants owned by the Trust.
      (2) This percentage is calculated based on 9,350,297 shares of the Common Stock issued and outstanding on September 20, 2023, as reported by the Issuer in the Issuer’s Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on September 20, 2023.

     

     

     

     

    CUSIP No. 09076W109 SCHEDULE 13G Page 4 of 7 Pages

     

    Item 1(a)  

    Name of Issuer:

     

    bioAffinity Technologies, Inc., a Delaware corporation (the “Company”)

       
    Item 1(b)  

    Address of Issuer’s Principal Executive Offices:

     

    22211 W Interstate 10, Suite 1206

    San Antonio, Texas 78257

       
    Item 2(a)   Name of Person Filing:
       
    Item 2(b)   Address of Principal Business Office or, if none, Residence:
       
    Item 2(c)  

    Citizenship:

     

    Roby P. Joyce (sometimes referred to as the “Reporting Person”)

    c/o bioAffinity Technologies, Inc.

    22211 W Interstate 10, Suite 1206

    San Antonio, Texas 78257

    Citizenship: The Reporting Person is a citizen of the United States.

     

    The Joyce Living Trust (sometimes referred to as the “Trust”)

    1092 Madeline Street

    New Braunfels, Texas 78132

    Citizenship: Texas

       
    Item 2(d)  

    Title of Class of Securities:

     

    Common Stock, par value $0.007 per share (“Common Stock”)

       
    Item 2(e)  

    CUSIP No.:

     

    09076W109

     

    Item 3. If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the Person Filing is:

     

      /x/ Not applicable.

     

      (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act;
           
      (b) ☐ Bank as defined in Section 3(a) (6) of the Exchange Act;
           
      (c) ☐ Insurance company as defined in Section 3(a) (19) of the Exchange Act;
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act;
           
      (e) ☐ An investment adviser in accordance with Rule 13d-1(b) (1) (ii) (E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b) (1) (ii) (F);
           
      (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b) (1) (ii) (G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act;
           
      (j) ☐ Group, in accordance with Rule 13d-1(b) (1) (ii) (J).

     

     

     

     

    CUSIP No. 09076W109 SCHEDULE 13G Page 5 of 7 Pages

     

    Item 4. Ownership

     

    As of the close of business on September 18, 2023, the Reporting Person held 0 shares of common stock.

     

    As of the close of business on September 18 2023, the Trust beneficially owned an aggregate of 603,129 shares of Common Stock, including 583,130 shares of common stock owned by the Trust and 19,999 shares of common stock issuable upon the exercise of warrants held by the Trust. The Reporting Person may be deemed to beneficially own the 603,129 shares beneficially owned by the Trust, as co-Trustee of the Trust, together with his wife, Joyce M. Joyce, each of whom may act unilaterally with regard to voting and disposition power with respect to the shares owned by the Trust, and of which the Reporting Person and Mrs. Joyce are the beneficiaries.

     

    The following sets forth in tabular format the share ownership of each of the Reporting Persons:

     

      (a) Amount beneficially owned: 603,129 shares of Common Stock
         
      (b) Percent of class: 6.44% (which percentage is calculated based on 9,350,297 shares of the Common Stock issued and outstanding on September 20, 2023, as reported by the Issuer in the Issuer’s Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on September 20, 2023)
         
      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote:
         
        See Cover Pages Items 5-9.
         
      (ii) shared power to vote or to direct the vote:
         
        See Cover Pages Items 5-9.
         
      (iii) sole power to dispose or to direct the disposition of:
         
        See Cover Pages Items 5-9.
         
      (iv) shared power to dispose or to direct the disposition of:
         
        See Cover Pages Items 5-9.

     

    Item 5.   Ownership of Five Percent or Less of a Class.
         
        If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
         
    Item 6.   Ownership of More than Five Percent on Behalf of Another Person.
         
        Not applicable.
         
    Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
         
        Not applicable.
         
    Item 8.   Identification and Classification of Members of the Group.
         
        See Exhibit 99.1.
         
    Item 9.   Notice of Dissolution of Group.
         
        Not applicable.
         
    Item 10.   Certifications.
         
        By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    [signature page follows]

     

     

     

     

    CUSIP No. 09076W109 SCHEDULE 13G Page 6 of 7 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 10, 2023

     

      /s/ Roby P. Joyce
      Roby P. Joyce
       
      THE JOYCE LIVING TRUST
       
      By: /s/ Roby P. Joyce
        Roby P. Joyce, Trustee

     

     

     

     

    Exhibit 99.1

     

    Joint Filing Agreement

     

    The undersigned hereby agree that the Statement on Schedule 13G dated October 10, 2023 with respect to the Common Stock, $0.007 par value per share, of bioAffinity Technologies, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

     

    Dated: October 10, 2023

     

    /s/ Roby P. Joyce   THE JOYCE LIVING TRUST
    ROBY P. JOYCE    
        By: /s/ Roby P. Joyce
          Roby P. Joyce, Trustee

     

     

    Get the next $BIAF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIAF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIAF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company's recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property Administration. The presentation at the 2025 RNA Therapeutics Conference, titled "Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas," highlights a novel therapeutic approach that uses small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting tw

      6/26/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

      Company research targets topical application for treatment of skin cancers bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company's novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity's innovative RNA-based therapeutic strategy and covers siRNAs

      6/24/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BIAF
    SEC Filings

    See more
    • Chief Operating Officer Reveles Xavier Trinidad was granted 21,604 shares, increasing direct ownership by 106% to 41,943 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:26 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Secretary, EVP, Gen. Counsel Zannes Timothy P was granted 8,641 shares, increasing direct ownership by 19% to 54,765 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:20 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • President & CEO Zannes Maria was granted 37,037 shares, increasing direct ownership by 15% to 280,359 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:23 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form POS AM filed by bioAffinity Technologies Inc.

      POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/27/25 4:53:08 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form POS AM filed by bioAffinity Technologies Inc.

      POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/27/25 4:50:32 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by bioAffinity Technologies Inc.

      DEFA14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/2/25 5:29:21 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Leadership Updates

    Live Leadership Updates

    See more
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

      5/20/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

      Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi

      11/4/24 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by bioAffinity Technologies Inc.

      SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)

      10/10/23 6:03:06 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Financials

    Live finance-specific insights

    See more
    • Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

      1/10/25 9:00:00 AM ET
      $BIAF
      $ENLV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car

      7/12/24 9:35:00 AM ET
      $BIAF
      $BTCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
    • BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target

      7/5/24 9:00:00 AM ET
      $BIAF
      $BIVI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations